Cargando…
On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
Head and neck cancers (HNC) represent a heterogeneous cluster of aggressive malignancies that account for 3% of all cancer cases in the UK. HNC is increasing in frequency particularly in the developing world, which is related to changes in risk factors. Unfortunately, the mortality rate is high, whi...
Autores principales: | Ward, Frank J., Dahal, Lekh N., Abu-Eid, Rasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165864/ https://www.ncbi.nlm.nih.gov/pubmed/30319637 http://dx.doi.org/10.3389/fimmu.2018.02182 |
Ejemplares similares
-
TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022) -
Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy
por: Abu Eid, Rasha
Publicado: (2019) -
Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018) -
Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review
por: Wells, Georgia, et al.
Publicado: (2021) -
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)